EZH2: novel therapeutic target for human cancer

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/86914

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/86914

题名:	EZH2: novel therapeutic target for human cancer
作者:	李龍緣;Long-Yuan Li
贡献者:	生物科技學系
关键词:	EZH2;Polycomb repressive;complex;Chromatin modification;Methylation
日期:	2014-03
上传时间:	2014-11-07 06:49:35 (UTC+0)
摘要:	Enhancer of Zeste homlog 2 (EZH2) is a catalytic subunit of epigenetic regulator Polycomb repressive complex 2 (PRC2), which trimethylates Lys 27 of histone H3, leading to silencing of the target genes that are involved in a variety of biological processes including tumor progression and stem cell maintenance. However, in addition to its canonical PRC2-dependent transcriptional repression function, EZH2 also acts as a gene activator in a noncanonical PRC2-independent manner. Overexpression of EZH2 has been detected in diverse cancers, and is associated with tumor malignancy. Moreover, activating mutations and inactivating mutations of EZH2 are also associated with certain types of cancer. Given EZH2’s multi-faceted function and role in cancer, context-specific strategy for targeting EZH2/EZH2-mediated signaling could serve as future targeted therapy/personalized medicine for human cancer.
關聯:	BioMedicine,4(1).
显示于类别:	[生物科技學系] 期刊論文

文件中的档案:

档案	大小	格式	浏览次数
index.html	0Kb	HTML	302	检视/开启

在ASIAIR中所有的数据项都受到原著作权保护.